Course handouts are now available
Click here
Come to London
WATCH to find out why
Site updates:
Programme Updates. Programme Overview and - Video Symposium on Challenging Cases now available.
Posters
(results will display both Free Papers & Poster)
Correlation of the corneal collagen cross-linking demarcation line using confocal microscopy and anterior segment optical coherence tomography in keratoconic patients
Poster Details
First Author: M.Grentzelos GREECE
Co Author(s): A. Plaka K. Tsoulnaras V. Diakonis D. Liakopoulos A. Pallikaris G. Kymionis
Abstract Details
Purpose:
To evaluate and compare the depth of the corneal stromal demarcation line after corneal collagen cross-linking (CXL) using two different methods: confocal microscopy and anterior segment optical coherence tomography (AS-OCT).
Setting:
Vardinoyiannion Eye Institute of Crete (VEIC), Faculty of Medicine, University of Crete, Heraklion, Crete, Greece
Methods:
In this prospective, comparative, interventional case series, 17 patients (18 eyes) with progressive keratoconus were enrolled. All patients underwent uneventful CXL treatment. One month postoperatively, corneal stromal demarcation line depth was measured in all patients by two independent observers using confocal microscopy and AS-OCT.
Results:
Mean corneal stromal demarcation line depth measured using confocal microscopy by the first observer was 306.22 ± 51.54 μm (245-417 μm) and by the second observer was 303.5 ± 46.98 μm (240-390 μm). The same measurements using AS-OCT were 300.67 ± 41.56 μm (240-385 μm) and 295.72 ± 41.01 μm (228 - 380μm) for the first and second observer, respectively. There was no statistically significant difference between confocal microscopy and AS-OCT measurements for both observers (p=0.3219 for the first and p=0.1731 for the second observer).
Conclusions:
Both confocal microscopy and AS-OCT have similar results in evaluating the depth of the corneal stromal demarcation line after CXL. Therefore, the noninvasive technology of AS-OCT may be used in the future as a simple and effective clinical method to evaluate the effectiveness of CXL treatment. FINANCIAL INTEREST: NONE